-+ 0.00%
-+ 0.00%
-+ 0.00%

*Oragenics: Continues to Advance ONP-002, Its Lead Intranasal Candidate for mTBI (Concussion), Through Phase IIa Feasibility Trial in Australia >OGEN

Dow Jones·08/28/2026 20:31:00

Please log in to view news